New hope for mechanism-based treatment of Parkinson's disease

被引：23

作者：

Bradbury, J

机构：

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 02期

关键词：

D O I：

10.1016/S1359-6446(04)03340-9

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

引用

收藏

页码：80 / 81

页数：2

相关论文

共 3 条

[1]

Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils [J].

Li, J ;

Zhu, M ;

Rajamani, S ;

Uversky, VN ;

Fink, AL .

CHEMISTRY & BIOLOGY, 2004, 11 (11) :1513-1521

[2]

A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease [J].

Loeb, MB ;

Molloy, DW ;

Smieja, M ;

Standish, T ;

Goldsmith, CH ;

Mahony, J ;

Smith, S ;

Borrie, M ;

Decoteau, E ;

Davidson, W ;

Mcdougall, A ;

Gnarpe, J ;

O'Donnell, M ;

Chernesky, M .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (03) :381-387

[3]

The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils [J].

Zhu, M ;

Rajamani, S ;

Kaylor, J ;

Han, S ;

Zhou, FM ;

Fink, AL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (26) :26846-26857